| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8964041 | Clinical Microbiology Newsletter | 2018 | 9 Pages |
Abstract
Several new antimicrobial agents with activity against Gram-negative bacteria have been approved by the Food and Drug Administration or are in late development. This review discusses the mode of action, spectrum of activity, resistance mechanism(s), and testing considerations for ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, delafloxacin, and plazomicin. Agents with activity against Gram-negative bacteria that are in late-phase development are also described.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Stephanie Ph.D., D(ABMM), Romney M. Ph.D., D(ABMM),